ETF Financing Ranking | GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) had a net financing buy-in of CNY 57.36 million, ranked in the first tier of the entire market-20260721
NewTimeSpace (newtimespace.com) News, Jul 21, 2026, GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.SH) increased by 0.26%, had a turnover of CNY 8.89 billion. Obtained financing buy-in of CNY 694.4 million, and financing repayment of CNY 637.04 million, with a net financing buy-in of CNY 57.36 million, ranked in the first tier of the entire market. (Data source: Wind)
Over a longer period, for the past 5 trading days of the fund, there were 3 days with net financing buy-in, totaling CNY 43.98 million, ranked in the first tier of the entire market. (Data source: Wind)
GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.SH), off-exchange connection (A type: 019670; C type: 019671).
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ETF Financing Ranking | GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) had a net financing buy-in of CNY 187.2 million on jun 30, ranked in the first tier of the entire market
- ETF Financing Ranking | GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) had a net financing buy-in of CNY 178.74 million on jun 10, ranked first in the entire market-20260610
- ETF Financing Ranking | GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) had a net financing buy-in of CNY 37.51 million, ranked in the first tier of the entire market-20260608